Lyell Immunopharma, Inc. (NASDAQ:LYEL – Get Free Report) was the target of a large decline in short interest in the month of September. As of September 30th, there was short interest totalling 10,660,000 shares, a decline of 19.4% from the September 15th total of 13,220,000 shares. Based on an average trading volume of 667,100 shares, the short-interest ratio is presently 16.0 days. Approximately 9.4% of the shares of the company are short sold.
Hedge Funds Weigh In On Lyell Immunopharma
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Opaleye Management Inc. bought a new stake in shares of Lyell Immunopharma during the 1st quarter worth $7,482,000. Caxton Associates LP boosted its holdings in shares of Lyell Immunopharma by 359.1% in the 1st quarter. Caxton Associates LP now owns 174,657 shares of the company’s stock worth $389,000 after purchasing an additional 136,611 shares in the last quarter. Invenomic Capital Management LP raised its holdings in shares of Lyell Immunopharma by 16.8% during the 1st quarter. Invenomic Capital Management LP now owns 871,525 shares of the company’s stock valued at $1,944,000 after buying an additional 125,110 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in Lyell Immunopharma by 1.4% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,731,477 shares of the company’s stock worth $15,013,000 after buying an additional 92,594 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC purchased a new position in shares of Lyell Immunopharma during the first quarter worth approximately $191,000. Hedge funds and other institutional investors own 66.05% of the company’s stock.
Lyell Immunopharma Stock Performance
Lyell Immunopharma stock traded down $0.02 during midday trading on Tuesday, reaching $1.17. 315,118 shares of the stock were exchanged, compared to its average volume of 895,586. The company’s fifty day moving average is $1.33 and its 200-day moving average is $1.86. Lyell Immunopharma has a 52 week low of $1.06 and a 52 week high of $3.26. The firm has a market cap of $298.28 million, a PE ratio of -1.30 and a beta of -0.53.
Analysts Set New Price Targets
Several equities analysts have recently weighed in on the stock. Bank of America reduced their target price on shares of Lyell Immunopharma from $9.00 to $6.00 and set a “buy” rating for the company in a research note on Thursday, June 27th. HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 price target on shares of Lyell Immunopharma in a report on Monday, August 19th.
Read Our Latest Research Report on Lyell Immunopharma
Lyell Immunopharma Company Profile
Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.
Recommended Stories
- Five stocks we like better than Lyell Immunopharma
- How to Invest in Blue Chip Stocks
- Goldman Sachs Earnings Reveal Market Moves Investors Can’t Ignore
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- AMD Gains Momentum With AI: Can It Beat Expectations?
- Why Are These Companies Considered Blue Chips?
- Lithium Grab: 2 Lithium Stocks That Could Be Takeover Targets
Receive News & Ratings for Lyell Immunopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyell Immunopharma and related companies with MarketBeat.com's FREE daily email newsletter.